NasdaqGS - Nasdaq Real Time Price USD
BioCryst Pharmaceuticals, Inc. (BCRX)
At close: November 7 at 4:00 PM EST
After hours: 7:27 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
412,579.00
331,412.00
270,827.00
157,170.00
17,812.00
Cost of Revenue
7,991.00
4,661.00
6,594.00
7,264.00
1,676.00
Gross Profit
404,588.00
326,751.00
264,233.00
149,906.00
16,136.00
Operating Expense
445,293.00
430,460.00
412,668.00
327,626.00
190,893.00
Operating Income
-40,705.00
-103,709.00
-148,435.00
-177,720.00
-174,757.00
Net Non Operating Interest Income Expense
-83,009.00
-92,462.00
-93,965.00
-59,232.00
-5,081.00
Other Income Expense
-411.00
-30,058.00
-1,983.00
55,143.00
-2,976.00
Pretax Income
-124,125.00
-226,229.00
-244,383.00
-181,809.00
-182,814.00
Tax Provision
-308.00
310.00
2,733.00
2,253.00
--
Net Income Common Stockholders
-123,817.00
-226,539.00
-247,116.00
-184,062.00
-182,814.00
Diluted NI Available to Com Stockholders
-123,817.00
-226,539.00
-247,116.00
-184,062.00
-182,814.00
Basic EPS
-0.61
-1.18
-1.33
-1.03
-1.09
Diluted EPS
-0.61
-1.18
-1.33
-1.03
-1.09
Basic Average Shares
205,226.25
192,198.00
185,908.00
179,117.00
167,267.00
Diluted Average Shares
205,226.25
192,198.00
185,908.00
179,117.00
167,267.00
Total Operating Income as Reported
-40,705.00
-103,709.00
-148,435.00
-177,720.00
-174,757.00
Total Expenses
453,284.00
435,121.00
419,262.00
334,890.00
192,569.00
Net Income from Continuing & Discontinued Operation
-123,817.00
-226,539.00
-247,116.00
-184,062.00
-182,814.00
Normalized Income
-123,407.02
-202,793.18
-245,549.43
-224,316.39
-179,838.00
Interest Income
15,641.00
15,777.00
5,127.00
62.00
9,420.00
Interest Expense
98,650.00
108,239.00
99,092.00
59,294.00
14,501.00
Net Interest Income
-83,009.00
-92,462.00
-93,965.00
-59,232.00
-5,081.00
EBIT
-25,475.00
-117,990.00
-145,291.00
-122,515.00
-168,313.00
EBITDA
-24,115.00
-116,335.00
-143,854.00
-121,738.00
-167,565.00
Reconciled Cost of Revenue
7,991.00
4,661.00
6,594.00
7,264.00
1,676.00
Reconciled Depreciation
1,360.00
1,655.00
1,437.00
777.00
748.00
Net Income from Continuing Operation Net Minority Interest
-123,817.00
-226,539.00
-247,116.00
-184,062.00
-182,814.00
Total Unusual Items Excluding Goodwill
-411.00
-30,058.00
-1,983.00
55,143.00
-2,976.00
Total Unusual Items
-411.00
-30,058.00
-1,983.00
55,143.00
-2,976.00
Normalized EBITDA
-23,704.00
-86,277.00
-141,871.00
-176,881.00
-164,589.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-1.02
-6,312.18
-416.43
14,888.61
--
12/31/2020 - 3/4/1994
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TGTX TG Therapeutics, Inc.
27.90
+2.69%
ARDX Ardelyx, Inc.
6.38
-1.69%
APLS Apellis Pharmaceuticals, Inc.
28.74
-0.31%
VRNA Verona Pharma plc
38.18
+1.57%
BNTX BioNTech SE
107.88
+1.16%
AUPH Aurinia Pharmaceuticals Inc.
8.34
+10.90%
IOVA Iovance Biotherapeutics, Inc.
12.28
+1.15%
ACAD ACADIA Pharmaceuticals Inc.
17.20
+8.93%
LXRX Lexicon Pharmaceuticals, Inc.
1.3000
+7.44%
CPRX Catalyst Pharmaceuticals, Inc.
23.25
+2.38%